Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Kathleen M. Dungan MD, MPH Advisory Board

Richard E. Pratley MD Associate Editor

See All Experts

story of the week

Published in Diabetes and

Journal Scan / Research · August 01, 2024

GLP-1 Receptor Agonists and SGLT2 Inhibitors for Treatment of Diabetes in Liver Transplant Recipients

Diabetes, Obesity & Metabolism

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Carolina Gonzalez-Lopez MD

Diabetes, Obesity & Metabolism

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients

Diabetes Obes Metab 2024 Jul 26;[EPub Ahead of Print], K Zheng, A Azhie, X You, M Naghibzadeh, E Tan, S Naimimohasses, VS Sridhar, S Gupta, S Chen, S Dash, C Tsien, N Selzner, L Lilly, E Jaeckel, M Woo, S Singh, D Cherney, M Bhat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

GLP-1 Receptor Agonists and SGLT2 Inhibitors for Treatment of Diabetes in Liver Transplant Recipients

Additional Info

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients

Further Reading

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Potential Off-Label Indication of Metformin for Ischaemic Stroke

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Effect of Long-Term Glycemic Burden on the Incidence of Diabetic Foot Ulcers

Weight Maintenance Using Cost-Effective Antiobesity Medications After 1 Year of GLP-1 Receptor Agonist Therapy

Trends in the Incidence of Young Adult–Onset Diabetes by Diabetes Type

Prognosis of Severe Hypoglycaemia and Diabetic Ketoacidosis in Adults Presenting to an Emergency Department

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Recently Updated